Comparative Pharmacology
Head-to-head clinical analysis: VIVACAINE versus XYLOCAINE 4 PRESERVATIVE FREE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: VIVACAINE versus XYLOCAINE 4 PRESERVATIVE FREE.
VIVACAINE vs XYLOCAINE 4% PRESERVATIVE FREE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
VIVACAINE is a local anesthetic that blocks the generation and conduction of nerve impulses by decreasing sodium ion permeability across the neuronal membrane.
Lidocaine stabilizes the neuronal membrane by inhibiting sodium ion influx through voltage-gated sodium channels, thereby blocking the initiation and propagation of action potentials, resulting in local anesthesia.
5-10 mL of 1% solution (50-100 mg) via submucosal infiltration or nerve block; maximum 500 mg per procedure.
Maximum 4.5 mg/kg (not to exceed 300 mg) via subcutaneous infiltration, epidural, or nerve block; repeat dosing after 30 minutes if needed.
None Documented
None Documented
Terminal elimination half-life: 6–8 hours in healthy adults. In patients with hepatic impairment, half-life may be prolonged up to 12–15 hours; in severe renal impairment (CrCl <30 mL/min), half-life may extend to 10–12 hours.
Terminal elimination half-life: ~1.5–2 hours (adults). Prolonged in hepatic impairment, congestive heart failure, or neonates.
Renal excretion of unchanged drug and metabolites accounts for approximately 85–90% of elimination, with about 10–15% excreted in feces via biliary clearance. Less than 2% of the dose is recovered unchanged in urine; the remainder is as glucuronide conjugates and other metabolites.
Renal: ~90% as metabolites (mostly 4-hydroxy-2,6-xylidine and conjugates); <10% unchanged. Biliary/fecal: minor.
Category C
Category C
Local Anesthetic
Local Anesthetic